The seasonal COVID-19 spike, combined with rising cases of seasonal flu and RSV, brings what has been called a “tripledemic.” ...

Pediatric RSV off-season outbreaks and positivity rates increased in China during the COVID-19 pandemic, according to study findings.

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

Vaxxas, has announced the company has been granted a licence to develop a next-generation vaccine antigen (DS2).

Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for ...

Sales of Pfizer’s new vaccine for respiratory syncytial virus were lower in the third quarter than during the same period last year, but the company pointed to signs of growing market share as reason ...

In the 2023–2024 respiratory syncytial virus (RSV) season, Spain implemented... The following is a summary of “Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in ...

RSV: A Growing Concern for the Vulnerable Respiratory ... for controlling its spread and minimizing complications. Rapid antigen tests for Strep A are widely available, and their accuracy allows ...

The next-generation DS2 RSV vaccine antigen licensed by Vaxxas was developed by scientists at the NIH’s Vaccine Research Center and the National Institute of Allergy and Infectious Diseases to prompt ...

Licensed to Vaxxas for worldwide use, this next-generation vaccine antigen (DS2) was developed and optimized by NIH’s scientists to prompt a more robust and durable immune response against RSV ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that the United States National Institutes of ...